Skip to main content
Qiagen N.V. logo

Qiagen N.V. — Investor Relations & Filings

Ticker · QIA ISIN · NL0015001WM6 LEI · 54930036WK3GMCN17Z57 F Manufacturing
Open in API
Filings indexed 627 across all filing types
Latest filing 2015-02-13 Major Shareholding Noti…
Country NL Netherlands
Listing F QIA

About Qiagen N.V.

https://www.qiagen.com/

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2015-02-13 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by QIAGEN N.V. for the quarterly period ended December 31, 2014. It includes detailed unaudited financial results for the quarter and full year 2014, with adjusted net sales, operating income, net income, and EPS figures. The document references non-GAAP financial measures and reconciliations, discusses business segments, geographic regions, and provides management commentary on performance and outlook. The presence of detailed financial data and analysis for a quarterly period, along with the SEC Form 6-K designation (used by foreign private issuers to report quarterly financial results), indicates this is an Interim / Quarterly Report. It is not an initial earnings release (ER) since it contains comprehensive financial data and analysis, nor is it an Annual Report (10-K) or other filing type. Therefore, the appropriate classification is Interim / Quarterly Report (IR). The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or certification.
2015-01-29 English
QIAGEN reports results for fourth quarter and full-year 2014
Earnings Release Classification · 98% confidence The document is titled "QIAGEN reports results for fourth quarter and full-year 2014" and contains detailed financial metrics, tables comparing FY 2014 vs FY 2013, and Q4 2014 vs Q4 2013 results, including adjusted net sales, operating income, and EPS. It also provides forward-looking guidance for 2015. This structure is characteristic of an Earnings Release (ER), which announces periodical financial results (quarterly and annual). Although it contains comprehensive data, the format strongly suggests it is the initial announcement of these results, rather than a full, formal regulatory filing like a 10-K or a comprehensive Interim Report (IR) which typically follows a more standardized regulatory structure. Since it explicitly reports quarterly and full-year results, 'ER' is the most appropriate classification. Q4 2014
2015-01-29 English
Major Shareholding Notification 2015
Major Shareholding Notification
2015-01-26 English
QIAGEN N.V. revises full-year 2014 adjusted EPS guidance and reaffirms fourth-quarter and full-year 2014 adjusted net sales guidance / announces offer to repurchase existing 2024 convertible notes
Capital/Financing Update Classification · 99% confidence The document is titled 'Ad-hoc Announcement according to § 15 WpHG' and discusses revisions to full-year guidance (EPS and net sales) and an announcement regarding an offer to repurchase existing convertible notes. This type of immediate, material disclosure, especially concerning financial guidance updates and significant financing/capital structure actions (like debt repurchase to optimize the balance sheet), is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it provides specific financial guidance updates and details a capital action (note repurchase), it aligns best with an Earnings Release (ER) which often includes guidance revisions, or a Capital/Financing Update (CAP). Given the primary focus on revising EPS guidance and reaffirming sales guidance, ER is a strong fit. However, the debt repurchase is a significant financing event. Since the document is an 'Ad-hoc Announcement' detailing both financial performance outlook adjustments and a specific capital structure move, and it is not a full report (like 10-K or IR), it fits the scope of an Earnings Release (ER) which frequently contains guidance updates, or potentially a Capital/Financing Update (CAP). Because the guidance revision is prominent, I will classify it as an Earnings Release (ER), as these often precede or accompany formal quarterly reports and contain the most timely financial outlook information. The document length is short (3773 chars), but it contains the core announcement, not just a notice to download a report.
2015-01-13 English
QIAGEN acquires Enzymatics enzyme solutions unit, a leading enabler of NGS applications
M&A Activity Classification · 99% confidence The document is a press release dated January 11, 2015, announcing the acquisition of the Enzyme Solutions Unit of Enzymatics by QIAGEN. It details the strategic rationale, financial implications (reaffirming guidance, mentioning expected charges), and partnership agreements. This type of announcement, detailing a significant corporate transaction (M&A), falls under the scope of Merger & Acquisition Activity (TAR). It is not a formal regulatory filing like a 10-K, nor is it a short announcement of a report (RPA/RNS).
2015-01-12 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.